Rituximab Inhibitor

Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5nM.

Du J, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007 May 18;282(20).
Du J, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem. 2007 May 18;282(20).
George J. et al. Rituximab: mechanism of action.Semin Hematol. 2010 April ; 47(2): 115-123.
George J. et al. Rituximab: mechanism of action.Semin Hematol. 2010 April ; 47(2): 115-123.
Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002 Jan;87(1):33-43.
Chow KU, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002 Jan;87(1):33-43.
Schliemann C, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009 Mar 5;113(10):2275-83.
Schliemann C, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009 Mar 5;113(10):2275-83.
Cartron G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use Crit Rev Oncol Hematol. 2007 Apr;62(1):43-52.
Cartron G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use Crit Rev Oncol Hematol. 2007 Apr;62(1):43-52.

Small volumes of Rituximab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5759555 is an inhibitor targeting Rituximab.